Patients enrolled in the study will be randomized to one of 3 treatment arms. Patients
randomized to Arm A will receive nivolumab every 2 weeks until disease progression.
Patients on Arm B will receive nivolumab combined with ipilimumab every 3 weeks for
4 doses followed by nivolumab alone every 3 weeks until disease progression. Patients
randomized to Arm C will receive ipilimumab monotherapy every 3 weeks for a total of
4 doses.
For study locations near you, please email me as the list is too extensive to post: cpoole@melanomainternational.org. You must be treatment naïve (no previous treatment)